Abstract Importance Tumour-infiltrating lymphocytes (TILs) have previously been found to
influence patient prognosis in other gastrointestinal cancers, for instance in colorectal …

Pancreatic cancer is an aggressive disease that is predicted to become the second leading
cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around …

Pancreatic cancer has a notoriously poor prognosis, exhibits persistent drug resistance, and
lacks a cure. Unique features of the pancreatic tumor microenvironment exacerbate …

Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration.
Dysregulation of the Hippo pathway has been recognized in a variety of human cancers …

Our understanding of the molecular mechanisms underlying cancer development and
evolution have evolved rapidly over recent years, and the variation from one patient to …

Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7%
due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes,
classical and basal. Recently, single-cell RNA sequencing has uncovered the coexistence …

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis due to the lack
of methods or biomarkers for early diagnosis and its resistance to conventional treatment …

Technological innovations, such as artificial intelligence (AI) and machine learning (ML),
have the potential to expedite the goal of precision medicine, especially when combined …

Simple Summary Stroma-targeting therapy in pancreatic ductal adenocarcinoma (PDAC)
has been extensively investigated, but no candidates have shown efficacy at the clinical trial …